
Mark Crossley, Indivior CEO
FDA approves another new type of opioid overdose antidote nasal spray
As more than 100,000 Americans continue to die every year from the opioid overdose epidemic, the FDA late Monday approved another new nasal spray that can be used in emergency settings when there’s an opioid overdose for people ages 12 and older.
UK-based Indivior acquired the nasal spray, now known commercially as Opvee (nalmefene), for $145 million upfront from Opiant Pharmaceuticals, and another potential $80 million if it hits certain milestones following approval. The spray is expected to hit the market in the fourth quarter, Indivior said.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters